CIC
ENTA icon

Cornercap Investment Counsel’s Enanta Pharmaceuticals ENTA Stock Holding History

Cornercap Investment Counsel’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,760
Closed -$178K – 563
2024
Q2 		$178K Sell
13,760
-25
-0.2% -$337 0.03% 549
2024
Q1 		$241K Buy
13,785
+249
+2% +$3.29K 0.04% 545
2023
Q4 		$127K Sell
13,536
-479
-3% -$4.46K 0.02% 555
2023
Q3 		$157K Buy
+14,015
New +$226K 0.03% 509
2023
Q2 		– Sell
-5,742
Closed -$232K – 600
2023
Q1 		$232K Hold
5,742
– – 0.04% 486
2022
Q4 		$267K Buy
+5,742
New +$262K 0.05% 479

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cornercap Investment Counsel's ENTA Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Enanta Pharmaceuticals (ENTA) in Q3 2024, closing a stake of 13,760 shares — an estimated $178K sold.

Cornercap Investment Counsel first reported a position in ENTA in Q4 2022 and held it in 6 quarters. The position peaked at $267K in Q4 2022. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Enanta Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 13,760 Enanta Pharmaceuticals shares in Q3 2024, an estimated $178K.
  • Cornercap Investment Counsel first reported a position in Enanta Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Cornercap Investment Counsel's Enanta Pharmaceuticals position peaked at $267K in Q4 2022.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.